leadf
logo-loader
viewDirecta Plus PLC
(
AIM:DCTAOTC:DTPKFFRA:88K
)

Directa Plus says peer-reviewed research supports the use of its graphene nano-materials in COVID face masks

The paper, which appeared in the journal iScience, said the company's G+ nanomaterials and those from graphene oxide provide a “critical opportunity to significantly increase face mask efficacy”

Directa Plus PLC -
Pictured is the G+ mask

Directa Plus PLC (LON:DCTA) said research has been published supporting the use of its ‘functionalised’ graphene as an antimicrobial in face masks.

The peer-reviewed paper, which appeared in the journal iScience, said the company's G+ nanomaterials and those from graphene oxide provide a “critical opportunity to significantly increase face mask efficacy”.

Directa said to date it has treated and supplied more than 240,000 meters of G+ graphene fabrics and produced and delivered more than one million G+ filters to fight the COVID-19 pandemic.

Quick facts: Directa Plus PLC

Follow
AIM:DCTA

Price: 130 GBX

Market Cap: £79.78 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of named herein, including the promotion by the Company of in any Content on the Site, the Company receives from said issuer annual cash...

FOR OUR FULL DISCLAIMER CLICK HERE

2 min read